SCHEMBL3078494

SCHEMBL3078494

CC(Oc1nsc(NC(=O)Oc2ccccc2)c1C(N)=O)c1c(F)ccc(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 2/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
CDK5 Q00535 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CNR2 P34972 1/20 0.36
KDR P35968 1/20 0.35
NTRK1 P04629 2/20 0.35
POLB P06746 1/20 0.34
MIF P14174 1/20 0.34
MAPT P10636 2/20 0.33
ACVR2A P27037 1/20 0.33
TGFBR2 P37173 1/20 0.33
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3090388 0.93 ALDH1A1 (0.48) ALDH1A1KMT2AMEN1LMNATP53
SCHEMBL3078955 0.93 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1LMNATP53
SCHEMBL3073922 0.86 ALDH1A1 (0.45) ALDH1A1KMT2AMEN1LMNATP53
SCHEMBL3094395 0.75 KDR (0.43) KDRNTRK1ACVR2ATGFBR2
SCHEMBL3081435 0.74 KDR (0.46) ALDH1A1KMT2AMEN1TP53GAA
SCHEMBL3077629 0.74 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1TP53GAA
SCHEMBL3094676 0.74 ALDH1A1 (0.47) ALDH1A1KMT2ALMNATP53CCNE1
SCHEMBL3090016 0.74 KDR (0.43) KDRNTRK1ACVR2ATGFBR2
SCHEMBL3096471 0.74 KDR (0.40) KDRNTRK1ACVR2ATGFBR2
SCHEMBL3084122 0.74 ALDH1A1 (0.48) ALDH1A1KMT2AMEN1TP53CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790902-B2 Isothiazole derivatives useful as anticancer agents PFIZER, INC. (US) 2010-09-07 US disclosed
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents PFIZER, INC. (US) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300249-A1 tyrosine kinase inhibitors such as 5-(3,3-Dimethyl-ureido)-3-heptyloxy-isothiazole-4-carboxylic acid amide, used for treating hyperproliferative disorders in mammals; anticarcinogenic agents; antiproliferative agents CDKN1A, TK1, CDK1 ALDH1A1 891/4885KMT2A 1265/4885MEN1 1782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.